LM-108 + penpulimab + oxaliplatin + capecitabine

LM-108 + penpulimab + oxaliplatin + capecitabine is an investigational combination regimen for the treatment of advanced solid tumors, including gastric cancer and other gastrointestinal malignancies. The regimen combines four agents with distinct mechanisms: - **LM-108** is a novel Fc-engineered anti-C-C chemokine receptor type 8 (CCR8) monoclonal antibody developed by LaNova Medicines. It selectively depletes tumor-infiltrating regulatory T cells (Tregs), thereby enhancing antitumor immune responses and inhibiting tumor growth[1][3][8]. - **Penpulimab** (AK105) is a human IgG1 anti-programmed cell death protein 1 (PD‑1) monoclonal antibody with engineered Fc mutations to eliminate effector functions such as ADCC, ADCP, and CDC. This design aims to reduce off-target immune effects while blocking PD‑1-mediated immunosuppression[6]. - **Oxaliplatin** is a platinum-based small molecule chemotherapeutic that induces DNA crosslinking and apoptosis in rapidly dividing cells. - **Capecitabine** is an oral prodrug of 5-fluorouracil, a pyrimidine analog that inhibits DNA synthesis in cancer cells[7]. This combination leverages both immunotherapy—by targeting CCR8+ Tregs and PD‑1 pathways—and cytotoxic chemotherapy to maximize antitumor efficacy. Clinical trials have shown promising activity in patients with advanced or refractory gastric cancer, especially those resistant to prior anti-PD‑1 therapy[2]. The regimen has also been explored for pancreatic cancer, non-small cell lung cancer, triple-negative breast cancer, colorectal cancer, and other solid tumors[1][4][5].

Other names

CapeOxXELOX